Kirby McInerney LLP is investigating potential claims against the Board of Directors of Solta Medical, Inc. ("Solta" or the "Company") (NASDAQ:SLTM) concerning the proposed acquisition of the Company by Valeant Pharmaceuticals International, Inc. ("Valeant") (NYSE:VRX). Under the terms of the definitive merger agreement, Solta stockholders will receive $2.92 in cash for each share of Solta owned, valuing the transaction at approximately $250 million.

The investigation concerns whether the Solta Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $2.92 per share proposed consideration adequately values Solta's common stock.

If you are a Solta stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at bwalker@kmllp.com, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.

Kirby McInerney LLP is a New York-based law firm concentrating in securities, shareholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.

Kirby McInerney LLP
J. Brandon Walker, Esq., 212-699-1145
888-529-4787
bwalker@kmllp.com